Zusammenfassung
Zielsetzung: Ziel der Studie war eine pharmakoökonomische Analyse der Behandlung von Schizophrenie-Patienten
mit Olanzapin, Risperidon und Haloperidol in Deutschland. Methodik: Die Analyse wurde mit Hilfe eines klinischen Entscheidungsmodells durchgeführt, das
von einem internationalen Expertenpanel entwickelt wurde. Das Modell einschließlich
der klinischen Daten (u. a. aus multinationalen klinischen Studien) über den Verlauf
der Erkrankung wurde übernommen. Daten zur Praxis bei der medizinischen Behandlung
von Schizophrenie sowie Kostendaten für Deutschland wurden in einem nationalen Expertenpanel
ermittelt und in das Modell integriert. Anschließend wurden eine Kostenanalyse und
eine Kosten-Effektivitäts-Analyse durchgeführt. Ergebnisse: Die Gesamtkosten der Therapie lagen bei allen 3 Therapien in der gleichen Größenordnung
(Risperidon 123 004 DM, Haloperidol 121 868 DM, Olanzapin 119 572 DM, jeweils pro
Patient für 5 Jahre). Die Kosteneffektivität von Risperidon bzw. Olanzapin war um
den Faktor 2,3 bzw. 2,5 besser als die von Haloperidol. Schlussfolgerungen: Bei Betrachtung der Gesamtkosten werden die hohen Tagestherapiekosten der atypischen
Neuroleptika durch Einsparungen bei der Behandlung von Negativsymptomatik und Rückfällen
ausgeglichen.
Cost-Analysis of Schizophrenia Treatment in Germany. A Comparison of Olanzapine, Risperidone
and Haloperidol Using a Clinical Decision Model
Aim: The aim of this study was the pharmacoeconomic analysis of schizophrenia treatment
with olanzapine, risperidone and haloperidol in Germany. Method: For the analysis a clinical decision model including clinical model parameters was
used that was developed by an international expert panel. Medical resource utilisation
and costs in Germany were determined by a national expert panel and integrated into
the model. Then a cost-analysis and a cost-effectiveness analysis were performed.
Results: The total costs per patient for 5 years were comparable for the 3 therapies (risperidone
DM 123 004, haloperidol DM 121 868, olanzapine DM 119 572). Cost-effectiveness of
risperidone and olanzapine was better by the factor 2.3 and 2.5, respectively, compared
to haloperidol. Conclusion: If total costs are considered, the high medication costs of new antipsychotics are
compensated by savings due to better efficacy in treatment of negative symptoms and
due to less relapses.
Schlüsselwörter:
Kostenanalyse - Schizophrenie - Modellierung
Key words:
Cost-analysis - Schizophrenia - Modeling
Literatur
1
Almond S, O’Donnell O.
Cost analysis of the treatment of schizophrenia in the UK: A comparison of Olanzapine
and Haloperidol.
Pharmacoeconomics.
1998;
13
575-588
2
Cohen L J, Test M A, Brown R L.
Suicide and schizophrenia: data from a prospective community treatment study.
Am J Psychiatry.
1990;
147
5
3
Davies A, Langley P C, Keks N A, Catts S V, Lambert T, Schweitzer I.
Risperidone versus haloperidol: II. Cost-effectiveness.
Clin Ther.
1998;
20
196-213
4 Edgell E T, Palmer C S, Revicki D A . et al .A cost effectiveness clinical decision
analysis for schizophrenia: results across four countries. Poster presentation at
the 11th European College of Neuro-Psycho-Pharmacology (ECNP) Congress. Paris; 1998
5
Foster R H, Goa K L.
Risperidone: a pharmacoeconomic review of its use in schizophrenia.
Pharmacoeconomics.
1998;
14
97-133
6
Gilbert P L, Harris M J, McAdams L A, Jeste D V.
Neuroleptic withdrawal in schizophrenic patients.
Arch Gen Psychiatry.
1995;
52
173-188
7
Hamilton S H, Genduso L A, Revicki D A.
Medical resource use and work and social outcomes for olanzapine compared with haloperidol
in the treatment of schizophrenia and other psychotic disorders.
Schizophrenia research.
1998;
29
148-149
8 Kay S R, Opler L A, Fiszbein A. Positive and Negative Syndrome Scale Manual. North
Tonawanda, NY; Multi-Health Systems 1986
9
Lehman A F, Thompson J W, Dixon L B, Scott F E.
Schizophrenia: treatment outcomes research.
Schiz Bull.
1995;
21
561-566
10 Mahmoud R A, Engelhart L M, Oster G . et al .Risperidone vs. Conventional antipsychotics:
a prospective randomized naturalistic effectiveness trial of outcomes in chronic schizophrenia
(poster). 36th Annual Meeting of the American College of Neuropsychopharmacology:
1997, Dec 8-12, Kameula, Hawaii.
11
Naber D.
A self-rating to measure subjective effects of neuroleptic drugs, relationships to
objective psychopathology, quality of life, compliance and other clinical variables.
Int Clin Psychopharmacol.
1995;
10
133-138
12
Nigthengale B S, Garrett L, Waugh S . et al .
Economic outcomes associated with the use of risperidone in a naturalistic group practice
setting.
Am J Manage Care.
1998;
4
360-366
13
Palmer C S, Revicki D A, Genduso L A, Hamilton S H, Brown R E.
A cost effectiveness clinical desicion analysis modell for schizophrenia.
Am J Managed Care.
1998;
43
345-355
14
von der Schulenburg J M, Uber A, Höffler J, Trenckmann U, Kissling W, Seemann U, Müller P,
Rüther E.
Untersuchungen zu den direkten und indirekten Kosten der Schizophrenie. Eine empirische
Analyse.
Gesundh ökon Qual manag.
1998;
3
81-87
15
Tollefson G D, Beasley C M, Tran P V, Street J S, Krueger J A, Tamura R N, Graffeo K A,
Thieme M E.
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective
and schizophreniform disorders: results of an international collaborative trial.
Am J Psychiatry.
1987;
154
457-465
16
Torrey E F.
Prevalence studies in schizophrenia.
Br J Psychiatry.
1987;
150
598-608
17
Tran P V, Hamilton S H, Kuntz A J, Potvin J H, Andersen S W, Beasley C, Tollefson G D.
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia
and other psychotic disorders.
J Clin Psychopharmacol.
1997;
17
407-418
18
Tran P V, Dellva M A, Tollefson G D, Beasley C M, Potvin J H, Kiesler G M.
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute
treatment of schizophrenia.
J Clin Psychiatry.
1997;
58
205-211
A. Spannheimer
Kendle GmbH & Co GMI KG
Stefan-George-Ring 6 81929 München
Telefon: Tel. 089-993913-0
Fax: Fax 089-993913-160
eMail: spannheimer.andrea@kendle.com